C4 Therapeutics Amends By-laws to Designate Exclusive Federal Forums for Securities Claims
On April 9, 2026, the Board of Directors of C4 Therapeutics, Inc. approved an amendment to the companyβs second amended and restated by-laws, effective immediately. The amendment designates the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving any complaints asserting causes of action arising under the Securities Act of 1933, the Securities Exchange Act of 1934, or their respective rules and regulations, unless the company provides written consent to an alternative forum. The Board approved this change in response to recent amendments to the General Corporation Law of the State of Delaware regarding forum selection provisions. Additionally, the by-laws maintain that the Court of Chancery of the State of Delaware remains the exclusive forum for derivative actions, fiduciary duty claims, and internal affairs doctrine claims. This administrative filing does not impact the company's clinical pipeline or financial guidance.